Hydromorphone Hcl

Verify with FDA CVM →

286 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
286
Total Reports
70
Deaths Reported
2450.0%
Death Rate

Active Ingredients

Hydromorphone Hcl

Administration Routes

UnknownIntramuscularIntravenousSubcutaneousOral

Species Affected

Dog 258
Cat 27
Rabbit 1

Most Affected Breeds

Retriever - Labrador 39
Dog (unknown) 23
Terrier - Bull - American Pit 15
Retriever - Golden 13
Domestic Shorthair 13
Chihuahua 9
Beagle 9
Boxer (German Boxer) 7
Terrier - Boston 7
Siberian Husky 6

Most Reported Reactions

Vomiting 64
Lethargy (see also Central nervous system depression in 'Neurological') 56
Elevated alanine aminotransferase (ALT) 42
Anorexia 39
Death by euthanasia 37
Other abnormal test result NOS 37
Elevated serum alkaline phosphatase (SAP) 34
Death 34
Elevated total bilirubin 31
Elevated liver enzymes 27
Diarrhoea 25
Leucocytosis NOS 23

Outcome Breakdown

Ongoing
126 (43.9%)
Recovered/Normal
78 (27.2%)
Euthanized
36 (12.5%)
Died
34 (11.8%)
Outcome Unknown
13 (4.5%)

Data Summary

Metric Value
Total adverse event reports 286
Reports involving death 70
Case-fatality rate (reported events) 2450.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Hydromorphone Hcl Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 286 adverse event reports referencing Hydromorphone Hcl, including 70 reports in which the animal died — a 2450.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Hydromorphone Hcl. Reported administration routes include Unknown, Intramuscular, Intravenous, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Hydromorphone Hcl reports are Dog (258 reports), Cat (27 reports), Rabbit (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (39), Dog (unknown) (23), Terrier - Bull - American Pit (15) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Hydromorphone Hcl are Vomiting (64), Lethargy (see also Central nervous system depression in 'Neurological') (56), Elevated alanine aminotransferase (ALT) (42), Anorexia (39). Of the 287 reports with a coded outcome, Ongoing is the leading category at 43.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Hydromorphone Hcl.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial